Valiant Laboratories

Valiant Laboratories EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Valiant Laboratories (VALIANTLAB.NS) as of Nov 4, 2026 is 140.23. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 20.44 — a change of 586.14% (higher).

EV/EBITDA

140.23

YoY

586.14%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Valiant Laboratories is 2026 140.23 . EV/EBITDA (Enterprise Value to EBITDA) of Valiant Laboratories was 2025 20.44 . It decreases by 586.14% higher compared to the previous year.

The Valiant Laboratories EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2021
7.24 INR
Jan 1, 2022
9.66 INR
Jan 1, 2023
10.77 INR
Jan 1, 2024
31.89 INR
Jan 1, 2025
20.44 INR
Jan 1, 2026
140.23 INR
The Valiant Laboratories EV/EBITDA history
YEAREV/EBITDAYoY
140.23+586.14%
20.44-35.92%
31.89+196.17%
10.77+11.49%
9.66+33.42%
7.24—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valiant Laboratories Stock analysis

What does Valiant Laboratories do? Valiant Laboratories Ltd manufactures paracetamol API/bulk drug for pharmaceutical applications, targeting medical conditions such as headache, muscle ache, arthritis, back ache, toothache, cold, and fever. The company operates a single manufacturing facility at Tarapur industrial estate, approximately 150 km from Nhava Sheva Port (JNPT), producing specialty chemicals and pharma intermediates for domestic and international markets. Its subsidiary, VALIANT ADVANCED SCIENCES PRIVATE LIMITED, supports the company's operations in the pharmaceutical sector. The firm's primary revenue comes from selling paracetamol API and specialty chemicals to pharmaceutical companies and distributors globally. Manufacturing focuses on high-demand applications like pain relief and fever treatment, with products distributed across India and abroad. The company leverages its Tarapur facility's proximity to Nhava Sheva Port for efficient export logistics. Valiant Laboratories Ltd serves the pharmaceutical industry by supplying essential active ingredients, particularly paracetamol, which is widely used in over-the-counter medications. The company's manufacturing capabilities for specialty chemicals and pharma intermediates cater to both domestic and international clients seeking reliable API sources. Its single-location production model ensures focused resource allocation for consistent output quality. Valiant Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valiant Laboratories stock

EV/EBITDA (Enterprise Value to EBITDA) of Valiant Laboratories is 140.23 in 2026.

EV/EBITDA (Enterprise Value to EBITDA) of Valiant Laboratories changed from 20.44 to 140.23, representing a 586.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Valiant Laboratories since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Valiant Laboratories with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Valiant Laboratories

All Key Metrics — Valiant Laboratories